

Special Issue

Innovative Treatments Based on Genomic Aberrations in Leukemia and Lymphoma

Message from the Guest Editors

Clinical management and risk stratification of leukemia/lymphoma depend largely on hematopathology findings. In the last few decades, testing algorithms have been implemented to support optimal risk-oriented therapy, leading to a large improvement in overall survival. In addition, large-scale genomic studies have identified multiple aberrations of prognostic significance that are not routinely tested by existing modalities. However, as chromosomal microarray analysis (CMA) and next-generation sequencing (NGS) technologies are increasingly used in the clinical management of hematologic malignancies, these abnormalities may be more readily detected. CMA and NGS significantly impact treatment by guiding the selection of targeted therapies, customizing chemotherapy regimens, and facilitating personalized approaches such as immunotherapy and bone marrow transplantation. These technologies allow for more precise treatment planning, ultimately improving efficacy and reducing side effects, while also aiding in monitoring minimal residual disease to predict relapse and adjust therapies accordingly.

Guest Editors

Prof. Dr. Vera Ulrike Bacher
Department of Hematology, University Hospital Bern, 3010 Bern,
Switzerland

Dr. Ashwini K. Yenamandra
Vanderbilt University Medical Center, Nashville, TN, USA

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/217916

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)